BioSpace News Archive

Biodesix, Inc. announced Scott Hutton, Chief Executive Officer of Biodesix, will present at Cowen’s 42nd Annual Healthcare Conference being held virtually March 7-9, 2022.

Organon today announced the appointment of Meghan Rivera as US Managing Director.

Gb Sciences, Inc., a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent by the U.S. Patent and Trademark Office for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced that it will participate in two upcoming investor conferences in March.

Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T.

Dyve Biosciences, Inc., a clinical-stage biotech company applying its proprietary transdermal drug delivery technology to a broad pipeline of clinical assets, announced the appointment of Nicholas A. Saccomano, Ph.D., a seasoned biopharmaceutical professional with nearly 35 years of extensive research and development experience across multiple therapeutic areas, to lead its Scientific Advisory Board.

Nabriva Therapeutics plc announced that it has granted a non-statutory stock option to purchase an aggregate of 12,000 ordinary shares of Nabriva Therapeutics as an inducement to a newly hired employee.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that the US Food and Drug Administration (FDA) has awarded 510(k) clearance to the next generation StimRouter® Neuromodulation System for the treatment of chronic pain of peripheral nerve origin, excluding craniofacial pain.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the Cowen 42nd Annual Health Care Conference, a virtual event taking place March 7-9, 2022.